Drug Trial Radar · NCT04759885
Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep®
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
886
Actual
Start
Jun 18, 2020
Primary completion
Jul 16, 2021
Study completion Jul 16, 2021
Sponsor
- Lead sponsor
- NTC srlIndustry
- Sponsor type
- Industry
- First posted
- Feb 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this dose finding/comparative efficacy study is to first single out the most appropriate dose of mannitol for bowel preparation (phase II) and, subsequently, demonstrate the non-inferiority of the efficacy of single dose mannitol vs standard split 2L PEG ASC (Moviprep®) (phase III) in bowel preparation for colonoscopy .
Conditions
- Elective Colonoscopy
Interventions
Phase II: NTC015 low doseDrug
Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Phase II: NTC015 medium doseDrug
Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Phase II: NTC015 high doseDrug
Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Phase III: NTC015 selected doseDrug
Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)Drug
The instructions for product administration are followed according to the Summary of Product Characteristics. One treatment consists of two litres of Moviprep® taken according to split-dose regimen. The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II - Dose Finding: Proportion of Patients With Adequate Bowel CleansingTime frame: During the colonoscopy procedure, carried out within 7 days of the screening visit, the evaluation is performed
- Phase III - Non-inferiority: Proportion of Patients With Adequate Bowel CleansingTime frame: During the colonoscopy procedure, carried out within 7 days of the screening visit, the evaluation is performed, at least 4 hours after end of intake, following product instruction as per protocol
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
Centre Hospitalier Henri Duffaut
Avignon, France
Hospices civils de Lyon
Lyon, France
Hôpital Edouard Herriot
Lyon, France
Centre Hospitalier Universitaire de Montpellier
Montpellier, France
Klinikum der Stadt Ludwigshafen
Ludwigshafen, Germany
Praxis für Gastroenterologie und Fachärztliche Innere Medizin, Im Haus der Gesundheit
Ludwigshafen am Rhein, Germany
Katholisches Klinikum Mainz
Mainz, Germany
Klinikum Worms Medizinische Klinik II
Worms, Germany
Azienda Ospedaliero-Universitaria Maggiore della Carità
Novara, Italy
ASST Sette Laghi - Ospedale di Circolo e Fondazione Macchi
Varese, Italy
IRCCS "Saverio De Bellis"
Castellana Grotte, BA, Italy
Fondazione Poliambulanza - Istituto Ospedaliero
Brescia, BR, Italy
ASSL Carbonia - Presidio Ospedaliero CTO di Iglesias
Iglesias, CI, Italy
Ospedale Valduce
Como, CO, Italy
Fondazione Casa Sollievo Della Sofferenza
San Giovanni Rotondo, FG, Italy
ASST Rhodense - Presidi di Rho e Garbagnate
Garbagnate Milanese, MI, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano
Milan, MI, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, MI, Italy
IRCCS Ospedale San Raffaele
Milan, MI, Italy
Istituto Europeo di Oncologia
Milan, MI, Italy
IRCCS Policlinico San Donato
San Donato Milanese, MI, Italy
Azienda USL di Modena - Ospedale Ramazzini di Carpi
Carpi, MO, Italy
Azienda Ospedaliero Universitaria Pisana- Ospedale Cisanello
Pisa, PI, Italy
Centro di Riferimento Oncologico IRCCS
Aviano, PN, Italy
Policlinico Universitario A. Gemelli
Roma, RO, Italy
Presidio Ospedaliero Santa Chiara
Trento, TN, Italy
Ospedale Sacro Cuore
Negrar, VR, Italy
Irkutsk State Medical Academy of Postgraduate Education
Irkutsk, Russia
Clinical Hospital of Russian Railways N.A. Semashko
Moscow, Russia
Moscow Clinical Research and Practical Center of the Department of Health
Moscow, Russia
State Central Clinical Hospital A. N. Ryzhykh
Moscow, Russia
Railway Clinical Hospital
Rostov-on-Don, Russia
Private educational organization of higher education "Medical University "Reaviz"
Samara, Russia
Medical Center of Diagnostics and Prevention
Yaroslavl, Russia
Regional Oncological Clinical Hospital
Yaroslavl, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.